- Home
- NKX vs ORIC Comparison
NKX vs ORIC Comparison
Compare NKX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- ORIC
- Stock Information
- Founded
- NKX 2002
- ORIC 2014
- Country
- NKX United States
- ORIC United States
- Employees
- NKX N/A
- ORIC N/A
- Industry
- NKX Finance/Investors Services
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NKX Finance
- ORIC Health Care
- Exchange
- NKX Nasdaq
- ORIC Nasdaq
- Market Cap
- NKX 599.7M
- ORIC 735.3M
- IPO Year
- NKX N/A
- ORIC 2020
- Fundamental
- Price
- NKX $12.92
- ORIC $12.31
- Analyst Decision
- NKX
- ORIC Strong Buy
- Analyst Count
- NKX 0
- ORIC 9
- Target Price
- NKX N/A
- ORIC $18.75
- AVG Volume (30 Days)
- NKX 109.3K
- ORIC 825.1K
- Earning Date
- NKX 01-01-0001
- ORIC 03-10-2025
- Dividend Yield
- NKX 4.37%
- ORIC N/A
- EPS Growth
- NKX N/A
- ORIC N/A
- EPS
- NKX N/A
- ORIC N/A
- Revenue
- NKX N/A
- ORIC N/A
- Revenue This Year
- NKX N/A
- ORIC N/A
- Revenue Next Year
- NKX N/A
- ORIC N/A
- P/E Ratio
- NKX N/A
- ORIC N/A
- Revenue Growth
- NKX N/A
- ORIC N/A
- 52 Week Low
- NKX $9.78
- ORIC $6.33
- 52 Week High
- NKX $12.00
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- NKX 56.81
- ORIC 59.70
- Support Level
- NKX $12.62
- ORIC $9.95
- Resistance Level
- NKX $12.67
- ORIC $12.01
- Average True Range (ATR)
- NKX 0.12
- ORIC 0.86
- MACD
- NKX 0.03
- ORIC 0.04
- Stochastic Oscillator
- NKX 77.78
- ORIC 64.50
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.